C-reactive protein is an important biomarker for prognosis tumor recurrence and treatment response in adult solid tumors: A systematic review

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Shrotriya, Shiva ^a   Walsh, Declan ^a   Bennani Baiti, Nabila ^a   Thomas, Shirley ^a   Lorton, Cliona ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Our Lady's Hospice Ltd Dublin   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; TUMOR MARKER;

ARTICLE; BLADDER TUMOR; CANCER MORTALITY; CANCER PROGNOSIS; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; HUMAN; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG TUMOR; PANCREAS TUMOR; PREDICTIVE VALUE; PRIMARY TUMOR; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR RECURRENCE; ADULT; META ANALYSIS; METABOLISM; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

ADULT; BIOMARKERS, TUMOR; C-REACTIVE PROTEIN; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; PROGNOSIS; TREATMENT OUTCOME;

EID: 84957107641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0143080     Document Type: Article

References (255)

1. Cancer Facts and Figures 2012. American Cancer Society. 2012.
2. Christakis NA, Lamont EB. Extent and determinants of error in physicians' prognoses in terminally ill patients: prospective cohort study. West J Med. 2000 May; 172(5):310-3. PMID: 18751282. Pubmed Central PMCID: 1070876. Epub 2008/08/30. eng.
3. Glare PA, Sinclair CT. Palliative medicine review: prognostication. J Palliat Med. 2008 Jan-Feb; 11(1):84-103. PMID: 18370898. Epub 2008/03/29. eng. doi: 10.1089/jpm.2008.9992
4. McShane LM, Altman DG, Sauerbrei W. Identification of clinically useful cancer prognostic factors: what are we missing? J Natl Cancer Inst. 2005 Jul. 20;97(14):1023-5. PMID: 16030294. Epub 2005/07/21. eng.
5. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci. 1982;389:406-18. PMID: 6953917. Epub 1982/01/01. eng.
6. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem. 2004 Nov. 19;279(47):48487-90. PMID: 15337754. Epub 2004/09/01. eng.
7. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003 Jun; 111(12):1805-12. PMID: 12813013. Pubmed Central PMCID: 161431. Epub 2003/06/19. eng.
8. Whiteside T, editor. Cytokines in Human Health. Totowa, New Jersey: Humana Press Inc.; 2007.
9. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007 Jul; 27(9):793-806. PMID: 17505829. Epub 2007/05/17. eng.
10. Shishehbor MH, Bhatt DL, Topol EJ. Using C-reactive protein to assess cardiovascular disease risk. Cleve Clin J Med. 2003 Jul; 70(7):634-40. PMID: 12882386. Epub 2003/07/29. eng.
11. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation. 2004 Mar. 23;109(11):1349-53. PMID: 15023871. Epub 2004/03/17. eng.
12. Kushner I, Sehgal AR. Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med. 2002 Apr. 22;162(8):867-9. PMID: 11966336. Epub 2002/04/23. eng.
13. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006 Nov. 30;72(11):1605-21. PMID: 16889756. Epub 2006/08/08. eng.
14. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002 Dec. 19-26;420(6917):860-7. PMID: 12490959. Pubmed Central PMCID: 2803035. Epub 2002/12/20. eng.
15. Cleeland CS, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003 Jun. 1;97(11):2919-25. PMID: 12767108. Epub 2003/05/27. eng.
16. Barber MD F K, Ross JA. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumor necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci (Lond). 1999;96:83-7.
17. Mahmoud FA, Rivera NI. The role of C-reactive protein as a prognostic indicator in advanced cancer. Curr Oncol Rep. 2002 May; 4(3):250-5. PMID: 11937016. Epub 2002/04/09. eng.
18. Khan K, ter Riet G, Popay J, Nixon J, Kleijen J. Conducting a review, stage II: PHASE 5: study quality assessment. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews (CRD Report 4, 2nd ed) Centre for Reviews and Dissemination. 2001:5-20.
19. Lau F, Cloutier-Fisher D, Kuziemsky C, Black F, Downing M, Borycki E, et al. A systematic review of prognostic tools for estimating survival time in palliative care. J Palliat Care. 2007 Summer; 23(2):93-112. PMID: 17853845. Epub 2007/09/15. eng.
20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 Apr; 42(2):377-81. PMID: 18929686. Pubmed Central PMCID: 2700030. Epub 2008/10/22. eng. doi: 10.1016/j.jbi.2008.08.010
21. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. International journal of surgery (London, England). 2010;8(5):336-41. PMID: 20171303. Epub 2010/02/23. eng.
22. Deichmann M, Benner A, Waldmann V, Bock M, Jackel A, Naher H. Interleukin-6 and its surrogate Creactive protein are useful serum markers for monitoring metastasized malignant melanoma. J Exp Clin Cancer Res. 2000 Sep; 19(3):301-7. Epub 2001/01/06. eng. PMID: 11144523
23. Deichmann M, Kahle B, Moser K, Wacker J, Wust K. Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase. Br J Cancer. 2004 Aug. 16;91(4):699-702. PMID: 15280926. Pubmed Central PMCID: 2364774. Epub 2004/07/29. eng.
24. Lukaszewicz-Zajac M, Mroczko B, Kozlowski M, Niklinski J, Laudanski J, Siewko M, et al. Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). J Clin Lab Anal. 2012 Feb; 26(2):73-81. PMID: 22467322. Epub 2012/04/03. eng. doi: 10.1002/jcla.21486
25. Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 2012 Apr; 7(4):655-62. PMID: 22425914. Epub 2012/03/20. eng. doi: 10.1097/JTO.0b013e318244ffe1
26. Wigmore SJ, McMahon AJ, Sturgeon CM, Fearon KC. Acute-phase protein response, survival and tumour recurrence in patients with colorectal cancer. Br J Surg. 2001 Feb; 88(2):255-60. PMID: 11167877. Epub 2001/02/13. eng.
27. Zingg U, Forberger J, Rajcic B, Langton C, Jamieson GG. Association of C-reactive protein levels and long-term survival after neoadjuvant therapy and esophagectomy for esophageal cancer. J Gastrointest Surg. 2010 Mar; 14(3):462-9. PMID: 19937473. Epub 2009/11/26. eng. doi: 10.1007/s11605-009-1113-2
28. Ljungberg B, Grankvist K, Rasmuson T. Serum acute phase reactants and prognosis in renal cell carcinoma. Cancer. 1995 Oct. 15;76(8):1435-9. PMID: 8620420. Epub 1995/10/15. eng.
29. Masuda H, Kurita Y, Suzuki A, Kanbayashi T, Suzuki K, Fujita K. Prognostic factors for renal cell carcinoma: a multivariate analysis of 320 cases. Int J Urol. 1997 May; 4(3):247-53. PMID: 9255661. Epub 1997/05/01. eng.
30. Inoue T, Hashimura T, Iwamura H, Takahashi T, Segawa T, Kakehi Y, et al. Multivariate analysis of prognostic determinants after surgery for renal cell carcinoma at Himeji National Hospital. Hinyokika Kiyo. 2000 Apr; 46(4):229-34. PMID: 10845152. Epub 2000/06/09. eng.
31. Miyata Y, Koga S, Nishikido M, Noguchi M, Kanda S, Hayashi T, et al. Predictive values of acute phase reactants, basic fetoprotein, and immunosuppressive acidic protein for staging and survival in renal cell carcinoma. Urology. 2001 Aug; 58(2):161-4. PMID: 11489689. Epub 2001/08/08. eng.
32. Ito K, Yoshii H, Asakuma J, Sato A, Horiguchi A, Sumitomo M, et al. Clinical impact of the presence of the worst nucleolar grade in renal cell carcinoma specimens. Jpn J Clin Oncol. 2009 Sep; 39(9):588-94. Epub 2009/06/27. eng. doi: 10.1093/jjco/hyp068 PMID: 19556339
33. Tanaka M, Fujimoto K, Okajima E, Tanaka N, Yoshida K, Hirao Y. Prognostic factors of renal cell carcinoma with extension into inferior vena cava. Int J Urol. 2008 May; 15(5):394-8. Epub 2008/05/03. eng. doi: 10.1111/j.1442-2042.2008.02017.x PMID: 18452454
34. Wood SL, Rogers M, Cairns DA, Paul A, Thompson D, Vasudev NS, et al. Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer. Br J Cancer. 2010 Jun. 29;103(1):101-11. PMID: 20531413. Pubmed Central PMCID: 2905280. Epub 2010/06/10. eng. doi: 10. 1038/sj.bjc.6605720
35. Falkensammer CE, Thurnher M, Leonhartsberger N, Ramoner R. C-reactive protein is a strong predictor for anaemia in renal cell carcinoma: role of IL-6 in overall survival. BJU Int. 2011 Jun; 107(12):1893-8. PMID: 21070572. Epub 2010/11/13. eng. doi: 10.1111/j.1464-410X.2010.09817.x
36. Johnson TV, Ali S, Abbasi A, Kucuk O, Harris WB, Ogan K, et al. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma. J Urol. 2011 Oct; 186(4):1213-7. PMID: 21849188. Epub 2011/08/19. eng. doi: 10.1016/j.juro.2011.06.014
37. Michigan A, Johnson TV, Master VA. Preoperative C-reactive protein level adjusted for comorbidities and lifestyle factors predicts overall mortality in localized renal cell carcinoma. Mol Diagn Ther. 2011 Aug. 1;15(4):229-34. PMID: 21756006. Epub 2011/07/16. eng.
38. Naglieri E, Lopez M, Lelli G, Morelli F, Amodio A, Di Tonno P, et al. Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res. 2002 Sep-Oct; 22(5):3045-51. PMID: 12530040. Epub 2003/01/18. eng.
39. Inoue A, Kunitoh H, Sekine I, Sumi M, Tokuuye K, Saijo N. Radiation pneumonitis in lung cancer patients: a retrospective study of risk factors and the long-term prognosis. Int J Radiat Oncol Biol Phys. 2001 Mar. 1;49(3):649-55. PMID: 11172945. Epub 2001/02/15. eng.
40. Broom J, Heys SD, Whiting PH, Park KG, Strachan A, Rothnie I, et al. Interleukin 2 therapy in cancer: identification of responders. Br J Cancer. 1992 Dec; 66(6):1185-7. PMID: 1457363. Pubmed Central PMCID: 1978053. Epub 1992/12/01. eng.
41. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992 Jun. 15;52(12):3317-22. PMID: 1596890. Epub 1992/06/15. eng.
42. Fujikawa K, Matsui Y, Oka H, Fukuzawa S, Takeuchi H. Serum C-reactive protein level and the impact of cytoreductive surgery in patients with metastatic renal cell carcinoma. J Urol. 1999 Dec; 162(6):1934-7. PMID: 10569541. Epub 1999/11/24. eng.
43. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003 Feb. 10;88(3):348-53. PMID: 12569375. Pubmed Central PMCID: 2747541. Epub 2003/02/06. eng.
44. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer. 2004 Oct. 4;91(7):1236-8. PMID: 15354220. Pubmed Central PMCID: 2409897. Epub 2004/09/09. eng.
45. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005 Jan; 173(1):52-5. PMID: 15592024. Epub 2004/12/14.eng.
46. Peccatori J, Barkholt L, Demirer T, Sormani MP, Bruzzi P, Ciceri F, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma undergoing nonmyeloablative allogeneic stem cell transplantation. Cancer. 2005 Nov. 15;104(10):2099-103. PMID: 16220555. Epub 2005/10/13. eng.
47. Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer. 2006 Sep. 18;95(6):691-8. PMID: 16940978. Pubmed Central PMCID: 2360513. Epub 2006/08/31. eng.
48. Jagdev SP, Gregory W, Vasudev NS, Harnden P, Sim S, Thompson D, et al. Improving the accuracy of pre-operative survival prediction in renal cell carcinoma with C-reactive protein. Br J Cancer. 2010 Nov. 23;103(11):1649-56. PMID: 21063409. Pubmed Central PMCID: 2994232. Epub 2010/11/11. eng. doi: 10.1038/sj.bjc.6605973
49. Johnson TV, Abbasi A, Owen-Smith A, Young AN, Kucuk O, Harris WB, et al. Postoperative better than preoperative C-reactive protein at predicting outcome after potentially curative nephrectomy for renal cell carcinoma. Urology. 2010 Sep; 76(3):766 e1-5. PMID: 20394975. Epub 2010/04/17. eng.
50. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008 Apr; 101(8):959-63. PMID: 18190639. Epub 2008/01/15. eng. doi: 10.1111/j.1464-410X.2007.07363.x
51. Lamb GW, McArdle PA, Ramsey S, McNichol AM, Edwards J, Aitchison M, et al. The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer. BJU Int. 2008 Sep; 102(6):756-61. PMID: 18384626. Epub 2008/04/04. eng. doi: 10.1111/j.1464-410X.2008.07666.x
52. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol. 2006 Nov; 13(11):1365-70. PMID: 17083384. Epub 2006/11/07. eng.
53. Johnson TV, Abbasi A, Owen-Smith A, Young A, Ogan K, Pattaras J, et al. Absolute preoperative Creactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J Urol. 2010 Feb; 183(2):480-5. PMID: 20006861. Epub 2009/12/17. eng. doi: 10.1016/j.juro.2009.10.014
54. Cho DS, Kim SJ, Lee SH, Ahn HS, Kim YS, Kim SI. Prognostic significance of preoperative C-reactive protein elevation and thrombocytosis in patients with non-metastatic renal cell carcinoma. Korean J Urol. 2011 Feb; 52(2):104-9. PMID: 21379426. Pubmed Central PMCID: 3045714. Epub 2011/03/08. eng. doi: 10.4111/kju.2011.52.2.104
55. Ito K, Yoshii H, Sato A, Kuroda K, Asakuma J, Horiguchi A, et al. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J Urol. 2011 Aug; 186(2):430-5. PMID: 21679988. Epub 2011/06/18. eng. doi: 10.1016/j.juro.2011.03.113
56. Takayama T, Sugiyama T, Kai F, Suzuki T, Nagata M, Imanishi T, et al. Characteristics of aggressive variants in T1a renal cell carcinoma. J Cancer Res Clin Oncol. 2011 Nov; 137(11):1653-9. PMID: 21874513. Epub 2011/08/30. eng. doi: 10.1007/s00432-011-1040-y
57. Yuceyar S, Erturk S, Dirican A, Cengiz A, Saner H. The role of acute-phase reactant proteins, carcinoembryonic antigen and CA 19-9 as a marker in the preoperative staging of colorectal cancer: a prospective clinical study. Int Surg. 1996 Apr-Jun; 81(2):136-9. PMID: 8912078. Epub 1996/04/01. eng.
58. Kwon KA, Kim SH, Oh SY, Lee S, Han JY, Kim KH, et al. Clinical significance of preoperative serum vascular endothelial growth factor, interleukin-6, and C-reactive protein level in colorectal cancer. BMC Cancer. 2010;10:203. PMID: 20465852. Pubmed Central PMCID: 2886042. Epub 2010/05/15. eng. doi: 10.1186/1471-2407-10-203
59. Hannisdal E, Tveit KM, Theodorsen L, Host H. Host markers and prognosis in recurrent rectal carcinomas treated with radiotherapy. Acta Oncol. 1994;33(4):415-21. PMID: 8018375. Epub 1994/01/01. eng.
60. Chung YC, Chang YF. Significance of inflammatory cytokines in the progression of colorectal cancer. Hepatogastroenterology. 2003 Nov-Dec; 50(54):1910-3. PMID: 14696431. Epub 2003/12/31. eng.
61. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, et al. Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer. Br J Surg. 2007 Aug; 94(8):1028-32. PMID: 17437250. Epub 2007/04/18. eng.
62. Crozier JE, McMillan DC, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, et al. Tumor size is associated with the systemic inflammatory response but not survival in patients with primary operable colorectal cancer. J Gastroenterol Hepatol. 2007 Dec; 22(12):2288-91. PMID: 18031394. Epub 2007/11/23. eng.
63. van de Poll MC, Klaver YL, Lemmens VE, Leenders BJ, Nienhuijs SW, de Hingh IH. C-reactive protein concentration is associated with prognosis in patients suffering from peritoneal carcinomatosis of colorectal origin. Int J Colorectal Dis. 2011 Aug; 26(8):1067-73. PMID: 21476028. Epub 2011/04/09. eng. doi: 10.1007/s00384-011-1187-7
64. Bystrom P, Berglund A, Nygren P, Wernroth L, Johansson B, Larsson A, et al. Evaluation of predictive markers for patients with advanced colorectal cancer. Acta Oncol. 2012 Sep; 51(7):849-59. PMID: 22974092. Epub 2012/09/15. eng. doi: 10.3109/0284186X.2012.705020
65. Miyata H, Yamasaki M, Kurokawa Y, Takiguchi S, Nakajima K, Fujiwara Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med. 2011 Sep; 2(5):879-85. PMID: 22977592. Pubmed Central PMCID: 3440840. Epub 2012/09/15. Eng.
66. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Shibuya N, Kubota K. Clinical significance of tumor pathology for postoperative survival of patients undergoing surgery for stage IV colorectal cancer. Anticancer Res. 2012 Aug; 32(8):3291-7. PMID: 22843904. Epub 2012/07/31. eng.
67. Chung YC, Chang YF. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator. Eur J Gastroenterol Hepatol. 2003 Apr; 15(4):369-73. PMID: 12655256. Epub 2003/03/26. eng.
68. Sawaki A, Kanemitsu Y, Mizuno N, Takahashi K, Nakamura T, Ioka T, et al. Practical prognostic index for patients with metastatic pancreatic cancer treated with gemcitabine. J Gastroenterol Hepatol. 2008 Aug; 23(8 Pt 1):1292-7. PMID: 18700899. Epub 2008/08/15. eng. doi: 10.1111/j.1440-1746. 2006.04734.x
69. Tanaka T, Ikeda M, Okusaka T, Ueno H, Morizane C, Hagihara A, et al. Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy. Jpn J Clin Oncol. 2008 Nov; 38(11):755-61. PMID: 18845521. Epub 2008/10/11. eng. doi: 10.1093/jjco/hyn098
70. Haas M, Laubender RP, Stieber P, Holdenrieder S, Bruns CJ, Wilkowski R, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumour Biol. 2010 Aug; 31(4):351-7. PMID: 20480409. Epub 2010/05/19. eng. doi: 10.1007/s13277-010-0044-6
71. La Torre M, Nigri G, Cavallini M, Mercantini P, Ziparo V, Ramacciato G. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol. 2012 Sep; 19(9):2917-23. PMID: 22488099. Epub 2012/04/11. eng. doi: 10.1245/s10434-012-2348-9
72. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, et al. Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib. Oncology. 2010;79(5-6):355-62. PMID: 21430404. Epub 2011/03/25. eng. doi: 10.1159/000323486
73. Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, Onitsuka T. Postoperative serum C-reactive protein levels in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2010 Apr; 16(2):85-90. PMID: 20930660. Epub 2010/10/12. eng.
74. Gioulbasanis I, Pallis A, Vlachostergios PJ, Xyrafas A, Giannousi Z, Perdikouri IE, et al. The Glasgow Prognostic Score (GPS) predicts toxicity and efficacy in platinum-based treated patients with metastatic lung cancer. Lung Cancer. 2012 Aug; 77(2):383-8. PMID: 22551892. Epub 2012/05/04. eng. doi: 10.1016/j.lungcan. 2012.04.008
75. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012 Jan; 203(1):101-6. PMID: 21429472. Epub 2011/03/25. eng. doi: 10.1016/j.amjsurg.2010.09.030
76. Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012 Nov; 57(5):1013-20. PMID: 22732513. Epub 2012/06/27. eng. doi: 10.1016/j.jhep. 2012.06.022
77. Kinoshita A, Onoda H, Takano K, Imai N, Saeki C, Fushiya N, et al. Pretreatment serum C-reactive protein level predicts poor prognosis in patients with hepatocellular carcinoma. Med Oncol. 2012 Dec; 29(4):2800-8. PMID: 22460836. Epub 2012/03/31. eng. doi: 10.1007/s12032-012-0220-1
78. Tartour E, Blay JY, Dorval T, Escudier B, Mosseri V, Douillard JY, et al. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol. 1996 May; 14(5):1697-703. PMID: 8622090. Epub 1996/05/01. eng.
79. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE. Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res. 2011;13(3):R55. PMID: 21639875. Pubmed Central PMCID: 3218944. Epub 2011/06/07. eng. doi: 10.1186/bcr2891
80. Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol. 2011;9:18. PMID: 21294915. Pubmed Central PMCID: 3045973. Epub 2011/02/08. eng. doi: 10.1186/1477-7819-9-18
81. Morizane S. Serum C-reactive protein level is significant prognostic indicator in patients with advanced urothelial cancer treated with Gemcitabine-Cisplatin or Carboplatin-preliminary results. Central European Journal of Urology. 2012;65(2):62-6. doi: 10.5173/ceju.2012.02.art1 PMID: 24578930
82. Obata J, Kikuchi E, Tanaka N, Matsumoto K, Hayakawa N, Ide H, et al. C-reactive protein: A biomarker of survival in patients with localized upper tract urothelial carcinoma treated with radical nephroureterectomy. Urol Oncol. 2012 Nov. 8. PMID: 23141922. Epub 2012/11/13. Eng.
83. Yoshida S, Saito K, Koga F, Yokoyama M, Kageyama Y, Masuda H, et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008 Apr; 101(8):978-81. PMID: 18190628. Epub 2008/01/15. eng. doi: 10.1111/j.1464-410X. 2007.07408.x
84. Beer TM, Lalani AS, Lee S, Mori M, Eilers KM, Curd JG, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008 Jun; 112(11):2377-83. PMID: 18428198. Epub 2008/04/23. eng. doi: 10.1002/cncr.23461
85. Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology. 2011 Nov; 78(5):1131-5. PMID: 22054387. Epub 2011/11/08. eng. doi: 10.1016/j.urology.2011.07.1416
86. Shafique K, Proctor MJ, McMillan DC, Qureshi K, Leung H, Morrison DS. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):195-201. PMID: 22343838. Epub 2012/02/22. eng. doi: 10.1038/pcan. 2011.60
87. Polterauer S, Grimm C, Tempfer C, Sliutz G, Speiser P, Reinthaller A, et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 2007 Oct; 107(1):114-7. PMID: 17617445. Epub 2007/07/10. eng.
88. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008 Feb. 1;14(3):710-4. PMID: 18245530. Epub 2008/02/05. eng. doi: 10.1158/1078-0432. CCR-07-1044
89. Nakamura T, Matsumine A, Matsubara T, Asanuma K, Uchida A, Sudo A. Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 2012 Feb. 15;118(4):1055-61. PMID: 21761398. Epub 2011/07/16. eng. doi: 10.1002/cncr.26353
90. Kodama J, Miyagi Y, Seki N, Tokumo K, Yoshinouchi M, Kobashi Y, et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 1999 Jan; 82(1):107-10. PMID: 10192497. Epub 1999/04/07. eng.
91. Yudoh K, Matsui H, Kamanori M, Ohmori K, Yasuda T, Tsuji H, et al. Prognostic value of the doubling time of serum C-reactive protein and alkaline phosphatase levels in primary bone and soft tissue tumors. Jpn J Cancer Res. 1996 Dec; 87(12):1288-95. PMID: 9045965. Epub 1996/12/01. eng.
92. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009 May 1;27(13):2217-24. PMID: 19289618. Epub 2009/03/18. eng. doi: 10.1200/JCO.2008.19.8440
93. Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, et al. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost. 2011 Jan; 9(1):57-63. PMID: 20874781. Epub 2010/09/30. eng. doi: 10.1111/j.1538-7836.2010.04069.x
94. Del Fabbro E, Hui D, Nooruddin ZI, Dalal S, Dev R, Freer G, et al. Associations among hypogonadism, C-reactive protein, symptom burden, and survival in male cancer patients with cachexia: a preliminary report. J Pain Symptom Manage. 2010 Jun; 39(6):1016-24. PMID: 20457506. Epub 2010/05/12. eng. doi: 10.1016/j.jpainsymman. 2009.09.021
95. Ridwelski K, Meyer F, Ebert M, Malfertheiner P, Lippert H. Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Dig Dis. 2001;19(1):85-92. PMID: 11385255. Epub 2001/06/01. eng.
96. Gioulbasanis I, Georgoulias P, Vlachostergios PJ, Baracos V, Ghosh S, Giannousi Z, et al. Mini Nutritional Assessment (MNA) and biochemical markers of cachexia in metastatic lung cancer patients: interrelations and associations with prognosis. Lung Cancer. 2011 Dec; 74(3):516-20. PMID: 21632145. Epub 2011/06/03. eng. doi: 10.1016/j.lungcan. 2011.05.009
97. Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, et al. Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer. 2011;11:489. PMID: 22103888. Pubmed Central PMCID: 3226799. Epub 2011/11/23. eng. doi: 10.1186/1471-2407-11-489
98. Kohles N, Nagel D, Jungst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012 Feb; 33(1):33-40. PMID: 21931992. Epub 2011/09/21. eng. doi: 10.1007/s13277-011-0237-7
99. Hwang EC, Hwang IS, Yu HS, Kim SO, Jung SI, Hwang JE, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. Jpn J Clin Oncol. 2012 Oct; 42(10):955-60. PMID: 22844127. Epub 2012/07/31. eng.
100. Chua TC, Chong CH, Liauw W, Zhao J, Morris DL. Inflammatory markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg. 2012 Aug; 256(2):342-9. PMID: 22750758. Epub 2012/07/04. eng. doi: 10.1097/SLA.0b013e3182602ad2
101. Chua W, Clarke SJ, Charles KA. Systemic inflammation and prediction of chemotherapy outcomes in patients receiving docetaxel for advanced cancer. Support Care Cancer. 2012 Aug; 20(8):1869-74. PMID: 21986674. Epub 2011/10/12. eng. doi: 10.1007/s00520-011-1289-3
102. Chang CC, Sun CF, Pai HJ, Wang WK, Hsieh CC, Kuo LM, et al. Preoperative serum C-reactive protein and gastric cancer; clinical-pathological correlation and prognostic significance. Chang Gung Med J. 2010 May-Jun; 33(3):301-12. PMID: 20584508. Epub 2010/06/30. eng.
103. Nakanishi H, Araki N, Kudawara I, Kuratsu S, Matsumine A, Mano M, et al. Clinical implications of serum C-reactive protein levels in malignant fibrous histiocytoma. Int J Cancer. 2002 May 10;99(2):167-70. PMID: 11979429. Epub 2002/04/30. eng.
104. Mortensen RF, Rudczynski AB. Prognostic significance of serum CRP levels and lymphoid cell infiltrates in human breast cancer. Oncology. 1982;39(3):129-33. PMID: 7078935. Epub 1982/01/01. eng.
105. Lewenhaupt A, Ekman P, Eneroth P, Nilsson B. Tumour markers as prognostic aids in prostatic carcinoma. Br J Urol. 1990 Aug; 66(2):182-7. PMID: 1697204. Epub 1990/08/01. eng.
106. Ekman P, Lewenhaupt A. Serum tumour markers in human prostatic carcinoma. The value of a marker panel for prognostic information. Acta Oncol. 1991;30(2):173-5. PMID: 2029401. Epub 1991/01/01. eng.
107. Muller T, Marshall RJ, Cooper EH, Watson DA, Walker DA, Mearns AJ. The role of serum tumour markers to aid the selection of lung cancer patients for surgery and the assessment of prognosis. Eur J Cancer Clin Oncol. 1985 Dec; 21(12):1461-6. PMID: 3830727. Epub 1985/12/01. eng.
108. Deans DA, Wigmore SJ, de Beaux AC, Paterson-Brown S, Garden OJ, Fearon KC. Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer. Br J Surg. 2007 Dec; 94(12):1501-8. PMID: 17703501. Epub 2007/08/19. eng.
109. Kim DK, Oh SY, Kwon HC, Lee S, Kwon KA, Kim BG, et al. Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer. 2009;9:155. PMID: 19457231. Pubmed Central PMCID: 2694817. Epub 2009/05/22. eng. doi: 10.1186/1471-2407-9-155
110. Lukaszewicz-Zajac M, Mroczko B, Gryko M, Kedra B, Szmitkowski M. Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer. Clin Exp Med. 2011 Jun; 11(2):89-96. PMID: 20938721. Pubmed Central PMCID: 3087107. Epub 2010/10/13. eng. doi: 10.1007/s10238-010-0114-5
111. Heys SD, Ogston KN, Simpson WG, Walker LG, Hutcheon AW, Sarkar TK, et al. Acute phase proteins in patients with large and locally advanced breast cancer treated with neo-adjuvant chemotherapy: response and survival. Int J Oncol. 1998 Sep; 13(3):589-94. PMID: 9683798. Epub 1998/07/31. eng.
112. Tas F, Duranyildiz D, Argon A, Oguz H, Camlica H, Yasasever V, et al. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005;22(4):353-8. PMID: 16260852. Epub 2005/11/02. eng.
113. Kelly L, White S, Stone PC. The B12/CRP index as a simple prognostic indicator in patients with advanced cancer: a confirmatory study. Ann Oncol. 2007 Aug; 18(8):1395-9. PMID: 17513884. Epub 2007/05/22. eng.
114. Glare P. Clinical predictors of survival in advanced cancer. J Support Oncol. 2005 Sep-Oct; 3(5):331-9. PMID: 16218255. Epub 2005/10/13. eng.
115. Hayes DF, Bast RC, Desch CE, Fritsche H Jr., Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996 Oct. 16;88(20):1456-66. PMID: 8841020. Epub 1996/10/16. eng.
116. Schilsky RL, Taube SE. Tumor markers as clinical cancer tests-are we there yet? Semin Oncol. 2002 Jun; 29(3):211-2. PMID: 12063673. Epub 2002/06/14. eng.
117. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol. 2005 Aug; 2(8):416-22. PMID: 16482653. Epub 2006/02/17. eng.
118. Ko YJ, Kwon YM, Kim KH, Choi HC, Chun SH, Yoon HJ, et al. High-sensitivity C-reactive protein levels and cancer mortality. Cancer Epidemiol Biomarkers Prev. 2012 Nov; 21(11):2076-86. PMID: 23136255. Epub 2012/11/09. eng. doi: 10.1158/1055-9965. EPI-12-0611
119. Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J. Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis. 2011 Jun; 14(2):122-8. PMID: 21358753. Epub 2011/03/02. eng. doi: 10.1038/pcan. 2011.5
120. Nakatsu T, Motoyama S, Maruyama K, Usami S, Sato Y, Miura M, et al. Tumoral CRP expression in thoracic esophageal squamous cell cancers is associated with poor outcomes. Surg Today. 2012 Jul; 42(7):652-8. PMID: 22350301. Epub 2012/02/22. eng. doi: 10.1007/s00595-012-0147-3
121. Saito K, Tatokoro M, Fujii Y, Iimura Y, Koga F, Kawakami S, et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur Urol. 2009 May; 55(5):1145-53. PMID: 18930583. Epub 2008/10/22. eng. doi: 10.1016/j.eururo.2008.10.012
122. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative Creactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008 Aug; 180(2):515-9. PMID: 18550105. Epub 2008/06/14. eng. doi: 10. 1016/j.juro.2008.04.025
123. Yang SH, Huang CJ, Chang SC, Lin JK. Association of C-reactive protein gene polymorphisms and colorectal cancer. Ann Surg Oncol. 2011 Jul; 18(7):1907-15. PMID: 21293934. Epub 2011/02/05. eng. doi: 10.1245/s10434-011-1575-9
124. Slattery ML, Curtin K, Poole EM, Duggan DJ, Samowitz WS, Peters U, et al. Genetic variation in Creactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer. 2011 Jun. 1;128(11):2726-34. PMID: 20949557. Pubmed Central PMCID: 3229275. Epub 2010/10/16. eng. doi: 10. 1002/ijc.25721
125. Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer. 2003 Jan; 11(1):60-2. PMID: 12527956. Epub 2003/01/16. eng.
126. Crumley AB, Stuart RC, McKernan M, McDonald AC, McMillan DC. Comparison of an inflammationbased prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J Gastroenterol Hepatol. 2008 Aug; 23(8 Pt 2):e325-9. PMID: 17645468. Epub 2007/07/25.eng.
127. Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg. 2012 Sep; 204(3):294-9. PMID: 22444831. Epub 2012/03/27. eng. doi: 10.1016/j. amjsurg.2011.10.015
128. Wang CY, Lee TF, Fang CH, Chou JH. Fuzzy Logic-Based Prognostic Score for Outcome Prediction in Esophageal Cancer. IEEE Trans Inf Technol Biomed. 2012 Aug. 2. PMID: 22875252. Epub 2012/08/10. Eng.
129. Van Hemelrijck M, Eichholzer M, Faeh D, Rohrmann S. Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III. BMC Public Health. 2012;12:895. PMID: 23092358. Pubmed Central PMCID: 3549794. Epub 2012/10/25. eng. doi: 10.1186/1471-2458-12-895
130. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007 Aug; 22(8):881-6. PMID: 17245566. Epub 2007/01/25. eng.
131. Proctor MJ, Morrison DS, Talwar D, Balmer SM, O'Reilly DS, Foulis AK, et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study. Br J Cancer. 2011 Feb. 15;104(4):726-34. PMID: 21266974. Pubmed Central PMCID: 3049591. Epub 2011/01/27. eng. doi: 10.1038/sj.bjc.6606087
132. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med. 2006 Feb; 119(2):166 e17-28. PMID: 16443421. Epub 2006/01/31. eng.
133. Koc M, Taysi S, Sezen O, Bakan N. Levels of some acute-phase proteins in the serum of patients with cancer during radiotherapy. Biol Pharm Bull. 2003 Oct; 26(10):1494-7. PMID: 14519962. Epub 2003/10/02. eng.
134. Bland M, editor. An Introduction to Medical Statistics. 3rd ed. NY: Oxford University Press; 2002.
135. Heikkila K, Ebrahim S, Lawlor DA. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health. 2007 Sep; 61(9):824-33. PMID: 17699539. Pubmed Central PMCID: 2703800. Epub 2007/08/19. eng.
136. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb. 17;357(9255):539-45. PMID: 11229684. Epub 2001/03/07. eng.
137. Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, et al. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang. Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):733s-40s. PMID: 17255302. Epub 2007/01/27. eng.
138. Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008 May; 9(5):375-80. PMID: 18473765. Epub 2008/05/14. eng.
139. Jones JM, McGonigle NC, McAnespie M, Cran GW, Graham AN. Plasma fibrinogen and serum Creactive protein are associated with non-small cell lung cancer. Lung Cancer. 2006 Jul; 53(1):97-101. PMID: 16698114. Epub 2006/05/16. eng.
140. Fearon KC, Voss AC, Hustead DS. Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 2006 Jun; 83(6):1345-50. PMID: 16762946. Epub 2006/06/10. eng.
141. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem. 2008 Feb; 54(2):343-9. PMID: 18156283. Epub 2007/12/25. eng.
142. Riley RD, Sauerbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. Br J Cancer. 2009 Apr. 21;100(8):1219-29. PMID: 19367280. Pubmed Central PMCID: 2676559. Epub 2009/04/16. eng. doi: 10.1038/sj.bjc.6604999
143. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int J Urol. 1998 Sep; 5(5):418-22. PMID: 9781427. Epub 1998/10/22. eng.
144. Hoffmann R, Franzke A, Buer J, Sel S, Oevermann K, Duensing A, et al. Prognostic impact of in vivo soluble cell adhesion molecules in metastatic renal cell carcinoma. Br J Cancer. 1999 Apr; 79(11-12):1742-5. PMID: 10206286. Pubmed Central PMCID: 2362808. Epub 1999/04/17. eng.
145. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br J Cancer. 2006 Mar. 27;94(6):781-4. PMID: 16523196. Pubmed Central PMCID: 3216422. Epub 2006/03/09. eng.
146. Royston P, Reitz M, Atzpodien J. An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer. 2006 Jun. 19;94(12):1785-8. PMID: 16736003. Pubmed Central PMCID: 2361333. Epub 2006/06/01. eng.
147. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007 Jan; 99(1):77-80. PMID: 16956357. Epub 2006/09/08. eng.
148. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer. 2007 Jan 15;109(2):205-12. PMID: 17149754. Epub 2006/12/07. eng.
149. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007 Sep. 15;110(6):1241-7. PMID: 17639589. Epub 2007/07/20. eng.
150. Guida M, Casamassima A, Monticelli G, Quaranta M, Colucci G. Basal cytokines profile in metastatic renal cell carcinoma patients treated with subcutaneous IL-2-based therapy compared with that of healthy donors. J Transl Med. 2007;5:51. PMID: 17953739. Pubmed Central PMCID: 2169206. Epub 2007/10/24. eng.
151. Kawata N, Nagane Y, Yamaguchi K, Ichinose T, Hirakata H, Takahashi S. How do symptoms have an impact on the prognosis of renal cell carcinoma? Int J Urol. 2008 Apr; 15(4):299-303. PMID: 18380815. Epub 2008/04/03. eng. doi: 10.1111/j.1442-2042.2008.01990.x
152. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J Urol. 2009 Mar; 181(3):1004-12; discussion 12. PMID: 19150550. Epub 2009/01/20. eng. doi: 10.1016/j.juro.2008.10.156
153. Kume H, Kakutani S, Yamada Y, Shinohara M, Tominaga T, Suzuki M, et al. Prognostic factors for renal cell carcinoma with bone metastasis: who are the long-term survivors? J Urol. 2011 May; 185(5):1611-4. PMID: 21419440. Epub 2011/03/23. eng. doi: 10.1016/j.juro.2010.12.037
154. Shinohara N, Abe T, Mochizuki T, Kashiwagi A, Kanagawa K, Maruyama S, et al. Is Memorial Sloan-Kettering Cancer Center risk classification appropriate for Japanese patients with metastatic renal cell carcinoma in the cytokine era? Urol Oncol. 2011 Sep. 26. PMID: 21956045. Epub 2011/10/01. Eng.
155. Soga N. The impact of preoperative serum albumin level and postoperative C-reactive protein nadir on the survival of patients with non-metastatic renal cell carcinoma with vessel thrombus after nephrectomy. Curr Urol. 2011;5:190-5.
156. Lamb GW, Aitchison M, Ramsey S, Housley SL, McMillan DC. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems. Br J Cancer. 2012 Jan 17;106(2):279-83. PMID: 22166802. Pubmed Central PMCID: 3261680. Epub 2011/12/15. eng. doi: 10.1038/bjc.2011.556
157. Qayyum T, McArdle PA, Lamb GW, Going JJ, Orange C, Seywright M, et al. Prospective study of the role of inflammation in renal cancer. Urol Int. 2012;88(3):277-81. PMID: 22377628. Epub 2012/03/02. eng. doi: 10.1159/000334971
158. Fujita T, Iwamura M, Ishii D, Tabata K, Matsumoto K, Yoshida K, et al. C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib. Int J Urol. 2012 Oct; 19(10):908-13. PMID: 22671963. Epub 2012/06/08. eng. doi: 10.1111/j.1442-2042.2012.03071.x
159. Yasuda Y, Saito K, Yuasa T, Kitsukawa S, Urakami S, Yamamoto S, et al. Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2012 Aug. 11. PMID: 22886358. Epub 2012/08/14. Eng.
160. Kawashima A, Tsujimura A, Takayama H, Arai Y, Nin M, Tanigawa G, et al. Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy. Int J Urol. 2012 Dec; 19(12):1050-7. PMID: 22860625. Epub 2012/08/07. eng. doi: 10.1111/j.1442-2042. 2012.03115.x
161. Bedke J, Chun FK, Merseburger A, Scharpf M, Kasprzyk K, Schilling D, et al. Inflammatory prognostic markers in clear cell renal cell carcinoma-preoperative C-reactive protein does not improve predictive accuracy. BJU Int. 2012 Dec; 110(11 Pt B):E771-7. PMID: 23134582. Epub 2012/11/09. eng. doi: 10.1111/j.1464-410X.2012.11642.x
162. Sim SH, Messenger MP, Gregory WM, Wind TC, Vasudev NS, Cartledge J, et al. Prognostic utility of pre-operative circulating osteopontin, carbonic anhydrase IX and CRP in renal cell carcinoma. Br J Cancer. 2012 Sep. 25;107(7):1131-7. PMID: 22918393. Pubmed Central PMCID: 3461155. Epub 2012/08/25. eng. doi: 10.1038/bjc.2012.360
163. Steffens S, Kohler A, Rudolph R, Eggers H, Seidel C, Janssen M, et al. Validation of CRP as prognostic marker for renal cell carcinoma in a large series of patients. BMC Cancer. 2012;12:399. PMID: 22958305. Pubmed Central PMCID: 3502607. Epub 2012/09/11. eng. doi: 10.1186/1471-2407-12-399
164. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum Creactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998 Oct; 176(4):335-8. PMID: 9817250. Epub 1998/11/17. eng.
165. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol. 2000 Sep; 7(8):617-23. PMID: 11005561. Epub 2000/09/27. eng.
166. McMillan DC, Canna K, McArdle CS. Systemic inflammatory response predicts survival following curative resection of colorectal cancer. Br J Surg. 2003 Feb; 90(2):215-9. PMID: 12555298. Epub 2003/01/30. eng.
167. McMillan DC, Canna K, McArdle CS. The effect of deprivation and the systemic inflammatory response on outcome following curative resection for colorectal cancer. Br J Cancer. 2003 Aug. 18;89(4):612-4. PMID: 12915865. Pubmed Central PMCID: 2376934. Epub 2003/08/14. eng.
168. Miki C, Konishi N, Ojima E, Hatada T, Inoue Y, Kusunoki M. C-reactive protein as a prognostic variable that reflects uncontrolled up-regulation of the IL-1-IL-6 network system in colorectal carcinoma. Dig Dis Sci. 2004 Jun; 49(6):970-6. PMID: 15309885. Epub 2004/08/18. eng.
169. Canna K, McMillan DC, McKee RF, McNicol AM, Horgan PG, McArdle CS. Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer. Br J Cancer. 2004 May 4;90(9):1707-9. PMID: 15150596. Pubmed Central PMCID: PMID: 2409754. Epub 2004/05/20. eng.
170. de Jong KP, Hoedemakers RM, Fidler V, Bijzet J, Limburg PC, Peeters PM, et al. Portal and systemic serum growth factor and acute-phase response after laparotomy or partial hepatectomy in patients with colorectal liver metastases: a prognostic role for C-reactive protein and hepatocyte growth factor. Scand J Gastroenterol. 2004 Nov; 39(11):1141-8. PMID: 15545174. Epub 2004/11/17. eng.
171. Nikiteas NI, Tzanakis N, Gazouli M, Rallis G, Daniilidis K, Theodoropoulos G, et al. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications. World J Gastroenterol. 2005 Mar. 21;11(11):1639-43. PMID: 15786541. Epub 2005/03/24. eng.
172. Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF, et al. The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 2005 Feb. 28;92(4):651-4. PMID: 15700032. Pubmed Central PMCID: 2361875. Epub 2005/02/09. eng.
173. Read JA, Choy ST, Beale PJ, Clarke SJ. Evaluation of nutritional and inflammatory status of advanced colorectal cancer patients and its correlation with survival. Nutr Cancer. 2006;55(1):78-85. PMID: 16965244. Epub 2006/09/13. eng.
174. Crozier JE, McKee RF, McArdle CS, Angerson WJ, Anderson JH, Horgan PG, et al. The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer. Br J Cancer. 2006 Jun. 19;94(12):1833-6. PMID: 16721360. Pubmed Central PMCID: 2361334. Epub 2006/05/25. eng.
175. Canna K, Hilmy M, McMillan DC, Smith GW, McKee RF, McArdle CS, et al. The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Colorectal Dis. 2008 Sep; 10(7):663-7. PMID: 18005189. Epub 2007/11/17. eng.
176. Leitch EF, Chakrabarti M, Crozier JE, McKee RF, Anderson JH, Horgan PG, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer. 2007 Nov. 5;97(9):1266-70. PMID: 17923866. Pubmed Central PMCID: 2360467. Epub 2007/10/10. eng.
177. Malik HZ, Prasad KR, Halazun KJ, Aldoori A, Al-Mukhtar A, Gomez D, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Ann Surg. 2007 Nov; 246(5):806-14. PMID: 17968173. Epub 2007/10/31. eng.
178. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007 Dec; 246(6):1047-51. PMID: 18043109. Epub 2007/11/29. eng.
179. Shiu YC, Lin JK, Huang CJ, Jiang JK, Wang LW, Huang HC, et al. Is C-reactive protein a prognostic factor of colorectal cancer? Dis Colon Rectum. 2008 Apr; 51(4):443-9. PMID: 18172726. Epub 2008/01/04. eng. doi: 10.1007/s10350-007-9133-z
180. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K, et al. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol. 2008 Dec. 1;98(7):540-4. PMID: 18937231. Epub 2008/10/22. eng. doi: 10.1002/jso.21154
181. Nozoe T, Mori E, Takahashi I, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator of colorectal carcinoma. Surg Today. 2008;38(7):597-602. PMID: 18612783. Epub 2008/07/10. eng. doi: 10.1007/s00595-007-3680-8
182. Groblewska M, Mroczko B, Wereszczynska-Siemiatkowska U, Kedra B, Lukaszewicz M, Baniukiewicz A, et al. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients. Clin Chem Lab Med. 2008;46(10):1423-8. PMID: 18844497. Epub 2008/10/11. eng. doi: 10.1515/CCLM.2008.278
183. Sharma R, Zucknick M, London R, Kacevska M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Colorectal Cancer. 2008 Sep; 7(5):331-7. PMID: 18794066. Epub 2008/09/17. eng. doi: 10.3816/CCC.2008.n. 044
184. Crozier JE, Leitch EF, McKee RF, Anderson JH, Horgan PG, McMillan DC. Relationship between emergency presentation, systemic inflammatory response, and cancer-specific survival in patients undergoing potentially curative surgery for colon cancer. Am J Surg. 2009 Apr; 197(4):544-9. PMID: 18614139. Epub 2008/07/11. eng. doi: 10.1016/j.amjsurg.2007.12.052
185. Ishizuka M, Kita J, Shimoda M, Rokkaku K, Kato M, Sawada T, et al. Systemic inflammatory response predicts postoperative outcome in patients with liver metastases from colorectal cancer. J Surg Oncol. 2009 Jul. 1;100(1):38-42. PMID: 19399786. Epub 2009/04/29. eng. doi: 10.1002/jso.21294
186. Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. The relationship between the local and systemic inflammatory responses and survival in patients undergoing curative surgery for colon and rectal cancers. J Gastrointest Surg. 2009 Nov; 13(11):2011-8; discussion 8-9. PMID: 19768511. Epub 2009/09/22. eng. doi: 10.1007/s11605-009-1034-0
187. Ishizuka M, Nagata H, Takagi K, Kubota K. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer. Ann Surg. 2009 Aug; 250(2):268-72. PMID: 19638907. Epub 2009/07/30. eng. doi: 10.1097/SLA.0b013e3181b16e24
188. Zacharakis M, Xynos ID, Lazaris A, Smaro T, Kosmas C, Dokou A, et al. Predictors of survival in stage IV metastatic colorectal cancer. Anticancer Res. 2010 Feb; 30(2):653-60. PMID: 20332485. Epub 2010/03/25. eng.
189. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Miki K, et al. Elevated C-reactive protein and hypoalbuminemia measured before resection of colorectal liver metastases predict postoperative survival. Dig Surg. 2010;27(4):285-90. PMID: 20689289. Epub 2010/08/07. eng. doi: 10.1159/000280021
190. Volkova E, Willis JA, Wells JE, Robinson BA, Dachs GU, Currie MJ. Association of angiopoietin-2, Creactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. Br J Cancer. 2011 Jan 4;104(1):51-9. PMID: 21081932. Pubmed Central PMCID: 3039823. Epub 2010/11/18. eng. doi: 10.1038/sj.bjc.6606005
191. Richards CH, Leitch EF, Horgan PG, Anderson JH, McKee RF, McMillan DC. The relationship between patient physiology, the systemic inflammatory response and survival in patients undergoing curative resection of colorectal cancer. Br J Cancer. 2010 Oct. 26;103(9):1356-61. PMID: 20877354. Pubmed Central PMCID: 2990607. Epub 2010/09/30. eng. doi: 10.1038/sj.bjc.6605919
192. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011 Jan; 2(1):95-101. PMID: 22977476. Pubmed Central PMCID: 3440627. Epub 2011/01/01. Eng.
193. Kocsis J, Meszaros T, Madaras B, Toth EK, Kamondi S, Gal P, et al. High levels of acute phase proteins and soluble 70 kDa heat shock proteins are independent and additive risk factors for mortality in colorectal cancer. Cell Stress Chaperones. 2011 Jan; 16(1):49-55. PMID: 20730518. Pubmed Central PMCID: 3024085. Epub 2010/08/24. eng. doi: 10.1007/s12192-010-0220-z
194. Roxburgh CS, Platt JJ, Leitch EF, Kinsella J, Horgan PG, McMillan DC. Relationship between preoperative comorbidity, systemic inflammatory response, and survival in patients undergoing curative resection for colorectal cancer. Ann Surg Oncol. 2011 Apr; 18(4):997-1005. PMID: 21042941. Epub 2010/11/03. eng. doi: 10.1245/s10434-010-1410-8
195. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Preoperative thrombocytosis is associated with survival after surgery for colorectal cancer. J Surg Oncol. 2012 Dec; 106(7):887-91. PMID: 22623286. Epub 2012/05/25. eng. doi: 10.1002/jso.23163
196. Furukawa K, Shiba H, Haruki K, Fujiwara Y, Iida T, Mitsuyama Y, et al. The Glasgow prognostic score is valuable for colorectal cancer with both synchronous and metachronous unresectable liver metastases. Oncol Lett. 2012 Aug; 4(2):324-8. PMID: 22844378. Pubmed Central PMCID: 3402729. Epub 2012/07/31. Eng.
197. Sugimoto K, Komiyama H, Kojima Y, Goto M, Tomiki Y, Sakamoto K. Glasgow prognostic score as a prognostic factor in patients undergoing curative surgery for colorectal cancer. Dig Surg. 2012;29(6):503-9. PMID: 23392422. Epub 2013/02/09. eng. doi: 10.1159/000346002
198. Ikeda M, Natsugoe S, Ueno S, Baba M, Aikou T. Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg. 2003 Aug; 238(2):197-202. PMID: 12894012. Pubmed Central PMCID: 1422696. Epub 2003/08/02. eng.
199. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, et al. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003 Aug; 83(4):248-52. PMID: 12884238. Epub 2003/07/29. eng.
200. Guillem P, Triboulet JP. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer. Dis Esophagus. 2005;18(3):146-50. PMID: 16045574. Epub 2005/07/28. eng.
201. Gockel I, Dirksen K, Messow CM, Junginger T. Significance of preoperative C-reactive protein as a parameter of the perioperative course and long-term prognosis in squamous cell carcinoma and adenocarcinoma of the oesophagus. World J Gastroenterol. 2006 Jun. 21;12(23):3746-50. PMID: 16773693. Epub 2006/06/15. eng.
202. Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006 Jun. 5;94(11):1568-71. PMID: 16685271. Pubmed Central PMCID: 2361311. Epub 2006/05/11. eng.
203. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008 Nov; 144(5):729-35. PMID: 19081014. Epub 2008/12/17. eng. doi: 10.1016/j.surg.2008.08.015
204. Wang CY, Hsieh MJ, Chiu YC, Li SH, Huang HW, Fang FM, et al. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol. 2009 Aug; 92(2):270-5. PMID: 19195729. Epub 2009/02/07. eng. doi: 10.1016/j.radonc.2009.01.002
205. Kobayashi T, Teruya M, Kishiki T, Kaneko S, Endo D, Takenaka Y, et al. Inflammation-based prognostic score and number of lymph node metastases are independent prognostic factors in esophageal squamous cell carcinoma. Dig Surg. 2010 Aug; 27(3):232-7. PMID: 20571271. Epub 2010/06/24. eng. doi: 10.1159/000276910
206. Fujiwara H, Suchi K, Okamura S, Okamura H, Umehara S, Todo M, et al. Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol. 2011 Jan 1;103(1):62-8. PMID: 21031427. Epub 2010/10/30. eng. doi: 10.1002/jso.21751
207. Vashist YK, Loos J, Dedow J, Tachezy M, Uzunoglu G, Kutup A, et al. Glasgow Prognostic Score is a predictor of perioperative and long-term outcome in patients with only surgically treated esophageal cancer. Ann Surg Oncol. 2011 Apr; 18(4):1130-8. PMID: 20981494. Epub 2010/10/29. eng. doi: 10. 1245/s10434-010-1383-7
208. Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour- and patient-related factors in patients undergoing potentially curative resection of oesophageal cancer. World J Surg. 2011 Aug; 35(8):1861-6. PMID: 21538187. Epub 2011/05/04. eng. doi: 10.1007/s00268-011-1130-7
209. Dutta S, Going JJ, Crumley AB, Mohammed Z, Orange C, Edwards J, et al. The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer. 2012 Feb. 14;106(4):702-10. PMID: 22240784. Pubmed Central PMCID: 3322960. Epub 2012/01/14. eng. doi: 10.1038/bjc.2011.610
210. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer. 2006 Dec. 4;95(11):1568-75. PMID: 17088911. Pubmed Central PMCID: 2360731. Epub 2006/11/08. eng.
211. Rashid SA, O'Quigley J, Axon AT, Cooper EH. Plasma protein profiles and prognosis in gastric cancer. Br J Cancer. 1982 Mar; 45(3):390-4. PMID: 6896153. Pubmed Central PMCID: 2010918. Epub 1982/03/01. eng.
212. Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMillan DC. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg. 2010 May; 14(5):781-7. PMID: 20148314. Epub 2010/02/12. eng. doi: 10.1007/s11605-010-1162-6
213. Crumley ABC. Interrelationship between tumor proliferation activity, leucocyte and macrophage infiltration, systemic inflammatory response and survival in patients selected for potentially curative resection. Ann Surg Oncol. 2011;18:2604-12. doi: 10.1245/s10434-011-1658-7 PMID: 21409484
214. de Mello J, Struthers L, Turner R, Cooper EH, Giles GR. Multivariate analyses as aids to diagnosis and assessment of prognosis in gastrointestinal cancer. Br J Cancer. 1983 Sep; 48(3):341-8. PMID: 6688531. Pubmed Central PMCID: 2011475. Epub 1983/09/01. eng.
215. Crumley AB, Stuart RC, McKernan M, McMillan DC. Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer? World J Surg. 2010 Oct; 34(10):2393-8. PMID: 20602101. Epub 2010/07/06. eng. doi: 10.1007/s00268-010-0641-y
216. Nozoe T, Iguchi T, Adachi E, Matsukuma A, Ezaki T. Preoperative elevation of serum C-reactive protein as an independent prognostic indicator for gastric cancer. Surg Today. 2011 Apr; 41(4):510-3. PMID: 21431483. Epub 2011/03/25. eng. doi: 10.1007/s00595-009-4297-x
217. Nozoe T, Iguchi T, Egashira A, Adachi E, Matsukuma A, Ezaki T. Significance of modified Glasgow prognostic score as a useful indicator for prognosis of patients with gastric carcinoma. Am J Surg. 2011 Feb; 201(2):186-91. PMID: 20832047. Epub 2010/09/14. eng. doi: 10.1016/j.amjsurg.2010.01. 030
218. Iwasa S, Nakajima TE, Nakamura K, Takashima A, Kato K, Hamaguchi T, et al. Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study. Int J Clin Oncol. 2011 Feb; 16(1):57-62. PMID: 20949367. Epub 2010/10/16. eng. doi: 10.1007/s10147-010-0135-9
219. Shimura T, Kitagawa M, Yamada T, Ebi M, Mizoshita T, Tanida S, et al. C-reactive protein is a potential prognostic factor for metastatic gastric cancer. Anticancer Res. 2012 Feb; 32(2):491-6. PMID: 22287736. Epub 2012/01/31. eng.
220. Jiang X, Hiki N, Nunobe S, Kumagai K, Kubota T, Aikou S, et al. Prognostic importance of the inflammationbased Glasgow prognostic score in patients with gastric cancer. Br J Cancer. 2012 Jul. 10;107(2):275-9. PMID: 22713657. Pubmed Central PMCID: 3394986. Epub 2012/06/21. eng. doi: 10.1038/bjc.2012.262
221. Kunisaki C, Takahashi M, Ono HA, Oshima T, Takagawa R, Kimura J, et al. Inflammation-based prognostic score predicts survival in patients with advanced gastric cancer receiving biweekly docetaxel and s-1 combination chemotherapy. Oncology. 2012;83(4):183-91. PMID: 22890015. Epub 2012/08/15. eng. doi: 10.1159/000341346
222. Jeong JH, Lim SM, Yun JY, Rhee GW, Lim JY, Cho JY, et al. Comparison of two inflammation-based prognostic scores in patients with unresectable advanced gastric cancer. Oncology. 2012;83(5):292-9. PMID: 22964877. Epub 2012/09/12. eng. doi: 10.1159/000342376
223. O'Gorman P, McMillan DC, McArdle CS. Prognostic factors in advanced gastrointestinal cancer patients with weight loss. Nutr Cancer. 2000;37(1):36-40. PMID: 10965517. Epub 2000/08/31. eng.
224. Elahi MM, McMillan DC, McArdle CS, Angerson WJ, Sattar N. Score based on hypoalbuminemia and elevated C-reactive protein predicts survival in patients with advanced gastrointestinal cancer. Nutr Cancer. 2004;48(2):171-3. PMID: 15231451. Epub 2004/07/03. eng.
225. McMillan DC, Wotherspoon HA, Fearon KC, Sturgeon C, Cooke TG, McArdle CS. A prospective study of tumor recurrence and the acute-phase response after apparently curative colorectal cancer surgery. Am J Surg. 1995 Oct; 170(4):319-22. PMID: 7573721. Epub 1995/10/01. eng.
226. Kara EK, M A; Erhan Y et. al. The value of serum C-reactive protein, carcinoembryonic antigen and cancer-associated antigen 19.9 as prognostic factors for recurrence in colorectal cancer. Journal of B U On. 2001;6(1):91-4.
227. Shimada H, Kitabayashi H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003 Jan; 133(1):24-31. PMID: 12563234. Epub 2003/02/04. eng.
228. Mohri Y, Tanaka K, Ohi M, Toiyama Y, Yasuda H, Inoue Y, et al. Inflammation-based prognostic score as a predictor of postoperative gastric cancer recurrence. Anticancer Res. 2012 Oct; 32(10):4581-4. PMID: 23060589. Epub 2012/10/13. eng.
229. Simpson WG, Heys SD, Whiting PH, Eremin O, Broom J. Acute phase proteins and recombinant IL-2 therapy: prediction of response and survival in patients with colorectal cancer. Clin Exp Immunol. 1995 Feb; 99(2):143-7. PMID: 7531626. Pubmed Central PMCID: 1534287. Epub 1995/02/01. eng.
230. Miyake H, Sakai I, Muramaki M, Kurahashi T, Takenaka A, Fujisawa M. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens. Int J Urol. 2009 May; 16(5):465-71. PMID: 19467119. Epub 2009/05/27. eng.
231. Ohno Y, Nakashima J, Ohori M, Hatano T, Tachibana M. Pretreatment neutrophil-to-lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol. 2010 Sep; 184(3):873-8. PMID: 20643463. Epub 2010/07/21. eng. doi: 10.1016/j.juro.2010.05.028
232. Melichar B, Krcmova L, Kalabova H, Holeckova P, Kasparova M, Plisek J, et al. Serum retinol, alphatocopherol and systemic inflammatory response in metastatic colorectal carcinoma patients treated with combination chemotherapy and cetuximab. Journal of nutritional science and vitaminology. 2010;56(4):222-6. PMID: 20924143. Epub 2010/10/07. eng.
233. Ishizuka M, Nagata H, Takagi K, Iwasaki Y, Kubota K. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen. Ann Surg Oncol. 2012 Oct; 19(11):3422-31. PMID: 22576063. Epub 2012/05/12. eng. doi: 10.1245/s10434-012-2384-5
234. Wilop S, Crysandt M, Bendel M, Mahnken AH, Osieka R, Jost E. Correlation of C-reactive protein with survival and radiographic response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer. Onkologie. 2008 Dec; 31(12):665-70. PMID: 19060504. Epub 2008/12/09. eng. doi: 10.1159/000165054
235. Gondo T, Nakashima J, Ohno Y, Choichiro O, Horiguchi Y, Namiki K, et al. Prognostic value of neutrophilto-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. Urology. 2012 May; 79(5):1085-91. PMID: 22446338. Epub 2012/03/27. eng. doi: 10.1016/j.urology.2011.11.070
236. Muller MW, Friess H, Koninger J, Martin D, Wente MN, Hinz U, et al. Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas. Am J Surg. 2008 Feb; 195(2):221-8. PMID: 18154768. Epub 2007/12/25. eng.
237. Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2011 Mar; 19(3):391-401. PMID: 20221887. Epub 2010/03/12. eng. doi: 10.1007/s00520-010-0832-y
238. Furukawa K, Uwagawa T, Iwase R, Haruki K, Fujiwara Y, Gocho T, et al. Prognostic factors of unresectable pancreatic cancer treated with nafamostat mesilate combined with gemcitabine chemotherapy. Anticancer Res. 2012 Nov; 32(11):5121-6. PMID: 23155291. Epub 2012/11/17. eng.
239. Frigeri M, De Dosso S, Castillo-Fernandez O, Feuerlein K, Neuenschwander H, Saletti P. Chemotherapy in patients with advanced pancreatic cancer: too close to death? Support Care Cancer. 2013 Jan; 21(1):157-63. PMID: 22648205. Epub 2012/06/01. eng. doi: 10.1007/s00520-012-1505-9
240. Haas M, Laubender RP, Klose C, Schulz C, Mansmann U, Boeck S, et al. External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy. Pancreas. 2012 Jul; 41(5):738-44. PMID: 22286380. Epub 2012/01/31. eng.
241. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012 Dec; 29(5):3092-100. PMID: 22476808. Epub 2012/04/06. eng. doi: 10.1007/s12032-012-0226-8
242. Hefler-Frischmuth K, Seebacher V, Polterauer S, Tempfer C, Reinthaller A, Hefler L. The inflammationbased modified Glasgow Prognostic Score in patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol. 2010 Mar; 149(1):102-5. PMID: 20080329. Epub 2010/01/19. eng. doi: 10.1016/j.ejogrb. 2009.12.027
243. Grimm M, Lazariotou M. Clinical relevance of a new pre-treatment laboratory prognostic index in patients with oral squamous cell carcinoma. Med Oncol. 2012 Sep; 29(3):1435-47. PMID: 21853343. Epub 2011/08/20. eng. doi: 10.1007/s12032-011-0045-3
244. Cho KS, Choi YD, Kim SJ, Kim CI, Chung BH, Seong do H, et al. A comprehensive prognostic stratification for patients with metastatic renal clear cell carcinoma. Yonsei medical journal. 2008 Jun. 30;49(3):451-8. PMID: 18581596. Pubmed Central PMCID: PMC2615339. Epub 2008/06/27. eng. doi: 10. 3349/ymj.2008.49.3.451
245. Komura K, Inamoto T, Black PC, Koyama K, Katsuoka Y, Watsuji T, et al. Prognostic significance of body mass index in Asian patients with localized renal cell carcinoma. Nutr Cancer. 2011;63(6):908-15. PMID: 21800976. Epub 2011/08/02. eng. doi: 10.1080/01635581.2011.594207
246. Hotta K, Sho M, Fujimoto K, Shimada K, Yamato I, Anai S, et al. Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma. Br J Cancer. 2011 Oct. 11;105(8):1191-6. PMID: 21934683. Pubmed Central PMCID: PMC3208496. Epub 2011/09/22. eng. doi: 10.1038/bjc.2011.368
247. Park YH, Baik KD, Lee YJ, Ku JH, Kim HH, Kwak C. Late recurrence of renal cell carcinoma> 5 years after surgery: clinicopathological characteristics and prognosis. BJU international. 2012;110(11b):E553-E8.
248. Ikeguchi M, Hatada T, Yamamoto M, Miyake T, Matsunaga T, Fukumoto Y, et al. Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2009;12(2):95-100. PMID: 19562463. Epub 2009/06/30. eng.
249. Takagawa R, Kunisaki C, Makino H, Kosaka T, Ono HA, Akiyama H, et al. Efficacy of chemoradiotherapy with low-dose cisplatin and continuous infusion of 5-fluorouracil for unresectable squamous cell carcinoma of the esophagus. Dis Esophagus. 2009;22(6):482-9. PMID: 19191850. Epub 2009/02/05. eng. doi: 10.1111/j.1442-2050.2008.00935.x
250. Lee WS, Baek JH, You DH, Nam MJ. Prognostic value of circulating cytokines for stage III colon cancer. The Journal of surgical research. 2013 Jun. 1;182(1):49-54. PMID: 23010514. Epub 2012/09/27. eng. doi: 10.1016/j.jss.2012.08.051
251. Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Jang JS, et al. Clinicopathologic significance of expression of nuclear factor-kappaB RelA and its target gene products in gastric cancer patients. World J Gastroenterol. 2012 Sep. 14;18(34):4744-50. PMID: 23002344. Pubmed Central PMCID: PMC3442213. Epub 2012/09/25. eng.
252. Garcea G, Ladwa N, Neal CP, Metcalfe MS, Dennison AR, Berry DP. Preoperative neutrophil-to-lymphocyte ratio (NLR) is associated with reduced disease-free survival following curative resection of pancreatic adenocarcinoma. World J Surg. 2011 Apr; 35(4):868-72. PMID: 21312035. Epub 2011/02/12. eng. doi: 10.1007/s00268-011-0984-z
253. Suh SY, Choi YS, Shim JY, Kim YS, Yeom CH, Kim D, et al. Construction of a new, objective prognostic score for terminally ill cancer patients: a multicenter study. Support Care Cancer. 2010 Feb; 18(2):151-7. PMID: 19381691. Epub 2009/04/22. eng. doi: 10.1007/s00520-009-0639-x
254. Six L, Polterauer S, Grimm C, Seebacher V, Tempfer C, Heinze G, et al. C-reactive protein serum levels are closely associated with lymph node status, but not with prognosis in patients with vulvar cancer. Eur J Obstet Gynecol Reprod Biol. 2008 Apr; 137(2):217-21. PMID: 17459567. Epub 2007/04/27. eng.
255. Kruse AL, Luebbers HT, Gratz KW. C-reactive protein levels: a prognostic marker for patients with head and neck cancer? Head & neck oncology. 2010;2:21. PMID: 20673375. Pubmed Central PMCID: PMC2921363. Epub 2010/08/03. eng.